<unk> s, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike<unk> s that modulate sodium/glucose channels in the intestinal mucosa. The foremost metabolic effect appears to show that this pharmaceutical class inhibits reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2<unk> .<unk> s are used in the treatment of type II diabetes mellitus (T2DM). Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in T2DM patients. Several medications of this class have been approved or are currently under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.
SGLT2 inhibitor
Chloride channel opener
COX-2 inhibitor
CYP17A1 inhibitor
Norepinephrine–dopamine disinhibitor
Beta-adrenergic agonist
Reuptake inhibitor
Protein kinase inhibitor